The CDC42BPB antibody is a tool used to detect CDC42 binding protein kinase beta (CDC42BPB), also known as MRCKβ, a serine/threonine kinase belonging to the myotonic dystrophy kinase-related CDC42-binding kinase (MRCK) family. This kinase regulates cytoskeletal dynamics by interacting with the small GTPase CDC42. playing a key role in cell motility, polarity, and morphogenesis. CDC42BPB is implicated in actin cytoskeleton reorganization, stress fiber formation, and cell migration through downstream targets like myosin light chain (MLC) and cofilin. Its activity is often studied in cancer, neuronal development, and immune response contexts.
Antibodies targeting CDC42BPB are utilized in techniques such as Western blotting, immunofluorescence, and immunohistochemistry to assess protein expression, localization, and post-translational modifications. They aid in exploring CDC42BPB's interaction networks and signaling pathways, particularly its crosstalk with Rho/ROCK signaling. Researchers also use these antibodies to investigate CDC42BPB's roles in diseases, including metastasis, neurological disorders, and cardiovascular conditions. Many commercially available antibodies are validated for specificity using knockout cell lines or siRNA knockdown. Host species (e.g., rabbit, mouse) and clonality (monoclonal/polyclonal) vary depending on application needs. Recent studies highlight CDC42BPB's potential as a therapeutic target, driving demand for reliable detection tools.